Headlines
UK Says Vaccine Protects Against Strain in Deadly Meningitis Outbreak
Published by Global Banking & Finance Review®
Posted on March 20, 2026
2 min readLast updated: March 20, 2026
Quick Summary
Britain’s health authorities say early lab tests confirm the Bexsero (MenB) vaccine should protect against the ST‑41/44 meningococcal strain driving a deadly outbreak in southeast England, where two people have died and vaccination and antibiotic responses are underway.
UK Health Officials Confirm Vaccine Protects Against Outbreak Meningitis Strain
Vaccine Effectiveness and Outbreak Response in Southeast England
Initial Laboratory Analysis and Vaccine Protection
LONDON, March 20 (Reuters) - Britain's health authorities said on Friday that early laboratory analysis had showed the vaccine being offered to students should protect against the strain of meningitis behind an outbreak in southeast England that has killed two people.
Identification of Meningitis Strain
The UK Health Security Agency said the strain belonged to a group of meningococci known as ST-41/44, which had been circulating in the country in recent years.
Reassurance and Ongoing Analysis
The confirmation that the Bexsero vaccine covers the strain had given "important reassurance," the agency said, while further analysis would continue.
Public Health Response and Vaccination Efforts
Vaccination and Antibiotic Administration
UKHSA said 2,360 people had now received vaccinations and about 9,840 courses of antibiotics had been administered as part of the response. As of Thursday evening, 18 cases had been confirmed and 11 others were under investigation.
Expansion of Vaccination Clinics
Authorities expanded vaccination clinics on Thursday after health officials warned they were not yet able to say the outbreak had been contained. Britain typically sees around one case of invasive meningitis per day, according to government estimates.
National Demand for MenB Vaccine
The outbreak has driven high demand for the MenB vaccine nationally, with pharmacy chain Boots reporting earlier this week that supplies across Britain were limited.
(Reporting by Sam Tabahriti, Editing by Paul Sandle)
Key Takeaways
- •The outbreak involves the ST‑41/44 clonal complex of Neisseria meningitidis serogroup B—a common lineage globally and in the UK—adding confidence that Bexsero, which targets antigens found in ST‑41/44 strains, offers protection. (elsevier.es)
- •UKHSA reports 2,360 people have been vaccinated and about 9,840 antibiotic courses administered as part of the response; 18 cases confirmed so far with 11 under investigation, exceeding the typical average of one invasive meningitis case per day in the UK. (en.wikipedia.org)
- •In the 2024/25 epidemiological year, England recorded 378 confirmed invasive meningococcal disease cases—most (over 82%) were MenB—with a case fatality rate around 8.2%, underlining the disease’s seriousness and the importance of timely vaccination. (gov.uk)
References
- Phenotypic and genomic surveillance of invasive Neisseria meningitidis isolates in Argentina (2015–2022): Clonal structure and vaccine implications | Revista Argentina de Microbiología / Argentinean J
- 2026 Kent meningitis outbreak
- Invasive meningococcal disease in England: annual laboratory-confirmed reports for epidemiological year 2024 to 2025 - GOV.UK
Frequently Asked Questions about UK says vaccine protects against strain in deadly meningitis outbreak
1What strain of meningitis is responsible for the UK outbreak?
The outbreak is caused by a group of meningococci known as ST-41/44.
2Is the current vaccine effective against the outbreak strain?
Yes, early laboratory analysis shows the Bexsero vaccine should protect against the circulating strain.
3How many people have been vaccinated in response to the outbreak?
2,360 people have received vaccinations so far.
4How many confirmed cases and deaths have resulted from the outbreak?
As of Thursday evening, there have been 18 confirmed cases and two deaths.
5Why is there high demand for the MenB vaccine?
The outbreak has increased demand nationally, causing reports of limited vaccine supplies across the UK.
